Bristol-Myers Squibb

Showing 15 posts of 146 posts found.

NICE approves first treatment for obstructive HCM for NHS use

June 2, 2023
Medical Communications Bristol-Myers Squibb, Cardiology, NHS, NICE, obstructive HCM

The National Institute for Health and Care Excellence (NICE) has announced that it has approved mavacamten (Camzyos) for the treatment …

Bristol Myers Squibb building in New Jersey

Bristol Myers Squibb psoriasis drug shows positive Phase III results

April 29, 2021
Bristol-Myers Squibb, bristol myers squibb, pharma, pharma news, psoriasis, psoriasis treatment

Bristol Myers Squibb’s investigational deucravacitinib drug, for the treatment of moderate-to-severe plaque psoriasis, has shown positive results in two Phase …

Molecular Templates signs cancer deal with BMS worth up to $1.3bn

February 15, 2021
Sales and Marketing Bristol-Myers Squibb, bristol myers squibb

Molecular Templates and Bristol Myers Squibb have entered into a worldwide strategic research collaboration worth up to $1.3 billion, to …


NICE recommends Bristol Myers Squibb’s skin cancer drug Opdivo for NHS use

February 12, 2021
Medical Communications Bristol-Myers Squibb, NICE, bristol myers squibb

NICE has issued final draft guidance recommending the routine use of Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) as an option …


Opdivo/Yervoy combo secures FDA approval for malignant pleural mesothelioma

October 6, 2020
Manufacturing and Production, Research and Development Bristol-Myers Squibb, Yervoy, bristol myers squibb, opdivo

Bristol Myers Squibb’s therapy regimen of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) has secured FDA approval for the first-line …


Bristol Myers Squibb announces positive results from Opdivo clinical trials

August 12, 2020
Research and Development Bristol-Myers Squibb, Cancer, bristol myers squibb

Bristol Myers Squibb has announced positive data from two Phase 3 clinical trials of its drug Opdivo. The first trial …


BMS’ Zeposia becomes first S1P receptor modulator available in Europe for relapsing remitting multiple sclerosis

May 28, 2020
Sales and Marketing Avonex, Bristol-Myers Squibb, EU, Europe, Zeposia, bristol myers squibb, multiple sclerosis

Bristol Myers Squibb is celebrating after its oral therapy Zeposia (ozanimod), secured European Commission for the treatment of relapsing remitting …


Positive CHMP opinion for BMS and Acceleron’s Reblozyl in transfusion-dependent anaemia sub-populations

May 1, 2020
Medical Communications, Sales and Marketing Acceleron, Bristol-Myers Squibb, EU, Reblozyl

Bristol Myers Squibb and Acceleron Pharma’s Reblozyl (luspatercept) has secured a positivr opinion from the European Medicines Agency’s Committee for Medicinal …


Phase 3 kidney cancer trial of Bristol Myers Squibb’s Opdivo and Exelixis’ Cabometyx meets primary endpoint

April 21, 2020
Manufacturing and Production BMS, Bristol-Myers Squibb, Exelixis, bristol myers squibb

Bristol Myers Squibb and Exelixis have announced that the Phase 3 trial investigating the combination of Opdivo (nivolumab) and Cabometyx …


Judge increases the amount of damages Gilead owes Bristol-Myers Squibb in CAR-T legal dispute

April 14, 2020
Manufacturing and Production Bristol-Myers Squibb, Gilead, bristol myers squibb

A judge has ruled that Gilead Sciences owe Bristol-Myers Squibb (BMS) additional funds after infringing on one of the company’s …


FDA approves BMS’ Zeposia in relapsing multiple sclerosis, but COVID-19 will delay its market entry

March 26, 2020
Sales and Marketing Bristol-Myers Squibb, COVID-19, Zeposia, coronavirus, multiple sclerosis, pharma

Bristol-Myers Squibb has secured approval with the FDA for Zeposia (ozanimod) 0.92mg in relapsing forms of multiple sclerosis (RMS), but …


Opdivo + cabiralizumab combo falls flat in advanced pancreatic cancer

February 19, 2020
Research and Development Bristol-Myers Squibb, Five Prime Therapeutics, Pancreatic cancer, cabiralizumab, opdivo, pharma

Five Prime Therapeutics and Bristol-Myers Squibb have confirmed that their randomised Phase 2 trial investigating the efficacy of the former’s …

Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia

December 11, 2019
Research and Development ASH 19, Bristol-Myers Squibb, acute myeloid leukaemia, pharma

Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data …


Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals

November 19, 2019
Manufacturing and Production, Sales and Marketing Bristol-Myers Squibb, MSD, keytruda, opdivo, pharma

MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 …

Latest content